Detail akcie Certara Rg online

Business Summary: Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Certara Inc revenues increased 11% to $315.2M. Net income totaled $4.3M vs. loss of $18.6M. Revenues reflect EMEA segment increase of 26% to $71.1M, Americas segment increase of 5% to $218.9M, Asia Pac segment increase of 27% to $25.2M. Net Income reflects Software segment income totaling $20.2M vs. loss of $7.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.12 to $0.03.